Compare Ginkgo Bioworks Holdings Inc (DNA) vs Alliant Energy Corporation (LNT) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.

The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.

LNT trades at $65.21, down 0.43% on the day, with a bullish technical signal despite mixed indicators. The company shows strong fundamentals with revenue growth to $4.36B in 2025 and net income of $810M, beating earnings estimates in three consecutive quarters. Analyst consensus is positive with a $77 price target and no sell ratings among 23 analysts. Recent news highlights institutional buying and a $13.4B capital investment plan supporting long-term growth.

LNT presents a favorable investment case with stable utility operations, consistent dividend growth, and strategic infrastructure investments. Key risks include rising debt levels (debt-to-asset ratio increased to 48.48% in 2025) and potential pressure from higher financing costs. The stock offers defensive value with a 3.29% dividend yield and exposure to growing data center demand in its service territories.